Summary

Bernard Marini is a Clinical Pharmacist Specialist in hematology. He hails from the Metro Detroit area, went to undergraduate and pharmacy school at the University of Michigan, and completed his PGY1 Pharmacy and PGY2 Hematology/Oncology residencies at the University of Michigan. In his clinical practice, Bernie primarily takes care of patients with acute leukemias, aggressive lymphomas, and other hematologic malignancies. His research focuses on improving clinical outcomes in hematology patients, advancing the Common Sense Oncology movement, and immunocompromised infectious diseases. Bernie also works with the pediatric brain tumor group on precision medicine initiatives and the investigation of blood brain barrier penetration of targeted therapies. He also hosts the WolverHeme Happy Hour Podcast: https://open.spotify.com/show/3VDDwc3BEQT2q10jjf8TsD?si=1eb5bb17b01d4de2. In his spare time, he enjoys playing ice hockey, coaching his daughters’ hockey and lacrosse teams, and brewing very average beer. 

Research Interests

  • Improving clinical outcomes in hematology patients

  • Asparaginase monitoring and pharmacokinetics

  • Immunocompromised infectious diseases

  • Oncology stewardship

  • Precision medicine in brain tumor patients & optimizing blood brain barrier penetration of chemotherapeutics

Awards

  • 2024 Nominated for University of Michigan College of Pharmacy Preceptor of the Year (not eligible - not adjunct), College of Pharmacy
  • 2023 University of Michigan Residency Preceptor of the Year Nominee, College of Pharmacy
  • 2023 Nominated for University of Michigan College of Pharmacy Preceptor of the Year, College of Pharmacy
  • 2022 University of Michigan Dept of Clinical Pharmacy Faculty Preceptor of the Year, College of Pharmacy
  • 2022 Nominated for 2021-2022 Preceptor of the Year Award (wasn't eligible now that I'm no longer adjunct), UM College of Pharmacy
  • 2022 Making a Difference Award, UMHS
  • 2022 HOPA Member Spotlight, HOPA
  • 2021 Making a Difference Award, UMHS

Selected Publications

  • Reid JH, Perissinotti AJ, Benitez L, Bixby DL, Burke P, Pettit K, Marini BL. Impact of prophylactic intrathecal chemotherapy on CNS relapse rates in AML patients presenting with hyperleukocytosis. Leuk Lymphoma. 2020 Apr;61(4):862-868. doi: 10.1080/10428194.2019.1691199. Epub 2019 Nov 18. PMID: 31739707.

  • Patel HP, Perissinotti AJ, Patel TS, Bixby DL, Marshall VD, Marini BL. Incidence and Risk Factors for Breakthrough Invasive Mold Infections in Acute Myeloid Leukemia Patients Receiving Remission Induction Chemotherapy. Open Forum Infect Dis. 2019 Apr 12;6(5):ofz176. doi: 10.1093/ofid/ofz176. PMID: 31123689; PMCID: PMC6524834.

  • Marini BL, Brown J, Benitez L, Walling E, Hutchinson RJ, Mody R, Jasty Rao R, Slagle L, Bishop L, Pettit K, Bixby DL, Burke PW, Perissinotti AJ. A single-center multidisciplinary approach to managing the global Erwinia asparaginase shortage. Leuk Lymphoma. 2019 Dec;60(12):2854-2868. doi: 10.1080/10428194.2019.1608530. Epub 2019 May 17. PMID: 31099289.

  • Vulaj V, Perissinotti AJ, Uebel JR, Nachar VR, Scappaticci GB, Crouch A, Bixby DL, Burke PW, Maillard I, Talpaz M, Marini BL. The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia. Leuk Res. 2018 Jul;70:91-96. doi: 10.1016/j.leukres.2018.05.011. Epub 2018 Jun 1. PMID: 29908418.

  • Linzey JR, Marini BL, Pasternak A, Smith C, Miklja Z, Zhao L, Kumar-Sinha C, Paul A, Harris N, Robertson PL, Hoffman LM, Chinnaiyan A, Mody R, Koschmann C. Development of the CNS TAP tool for the selection of precision medicine therapies in neuro-oncology. J Neurooncol. 2018 Mar;137(1):155-169. doi: 10.1007/s11060-017-2708-1. Epub 2017 Dec 12. PMID: 29235051; PMCID: PMC5823756.

  • Full Bibliography can be found here: https://www.ncbi.nlm.nih.gov/myncbi/1xaYt9Fhisf5w/bibliography/public/